Tilray Brands

Secular Legalization And Wellness Trends Will Transform EU Cannabis Industry

AnalystHighTarget

Not Invested

Community Contributor

Published

20 Aug 25

AnalystHighTarget's Fair Value

US$1.83

20.9% undervalued

11 Sep

US$1.45

-13.7%

You can edit this narrative until Aug 20 9:26 PM. Then, changes will post as Updates.

Author's Valuation

US$1.8320.9% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$1.83

20.9% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

4.37%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.45%

Calculation

US$222.68m

Earnings '28

13.36x

PE Ratio '28

US$2.97b

Market Cap '28

US$2.97b

Market Cap '28

1.35b

No. shares '28

US$2.21

Share Price '28

US$2.21 Share Price '28

Discounted to 2025 @ 6.45% p.a.

US$1.83

Fair Value '25